Helicobacter pylori and Gastroesophageal Reflux Disease: To Treat or Not to Treat?

O'Connor, H.J.; O’Moráin, Colm

doi:10.1080/003655201300191923

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Abstract: Gastroesophageal Reflux Disease; Helicobacter Pylori1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2002

2004

Publication Types

Select...

Article4

Book1

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 6 publications

(2 citation statements)

References 53 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is a dilemma at present as to the role of H. pylori in gastrooesophageal reflux disease (GORD) (28). None of the detected GORD cases were in the group of antrum-predominant gastritis.…”

Section: Discussionmentioning

confidence: 99%

Prognostic significance of antrum‐predominant gastritis in functional dyspepsia

Heikkinen

Vornanen²,

Hollmén³

et al. 2004

Scandinavian Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic significance of antrum‐predominant gastritis in functional dyspepsia

Heikkinen

Vornanen²,

Hollmén³

et al. 2004

Scandinavian Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

“…In a recent study from Olmsted County, approximately 20% of adults experienced heartburn or acid regurgitation at least once per week (1). Fifty per cent of the adult population is infected with Helicobacter pylori (2). Both GERD and H pylori infection are life-long conditions unless active measures are taken to treat them.…”

Section: Abstract: Gastroesophageal Reflux Disease; Helicobacter Pylorimentioning

confidence: 99%

Motion – Helicobacter pylori Causes or Worsens GERD: Arguments for the Motion

O’Moráin

Qasim

2002

Canadian Journal of Gastroenterology

View full text Add to dashboard Cite

There are several reasons for eradicating Helicobacter pylori in patients with chronic gastroesophageal reflux disease (GERD). Perhaps the most compelling is the evidence that chronic acid suppression therapy can lead to the development of atrophic gastritis, a premalignant condition, in patients with H pylori infection. Epidemiological data that suggest that H pylori is less prevalent in GERD patients than in control subjects may be susceptible to publication bias, and confounding social and environmental factors may also be involved. Although it has been thought that eradication of the organism might lead to increased esophageal acid exposure, this has not been demonstrated in practice. Studies that appeared to show that GERD could be provoked by antimicrobial therapy of duodenal ulcers also have methodological weaknesses. Underlying GERD symptoms might be unmasked after withdrawal of acid-suppression therapy, for reasons that are unrelated to H pylori. In fact, eradication of the organism has been shown to decrease heartburn in patients with peptic ulcer disease. When H pylori is successfully eradicated in patients with GERD, relapse rates are not increased, and the disease-free interval seems to be prolonged. Eradication of the organism is a wise policy in patients who face long term acid-suppression therapy for GERD.

show abstract